Clinical-Stage Biopharmaceutical Company
Appears in 1 story
Being acquired by Merck
Keytruda, the world's best-selling drug, generated $31.7 billion for Merck in 2025 — roughly 40% of the company's total revenue. Its key U.S. patents expire in 2028, and when they do, cheaper copies will enter the market and that revenue will begin to evaporate. Merck has now spent over $25 billion on three acquisitions in nine months to build the portfolio that will need to replace it.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
